Skip to main content
Erschienen in: Clinical Rheumatology 5/2017

27.02.2017 | Original Article

Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry

verfasst von: Dong-Jin Park, Sung Jae Choi, Kichul Shin, Hyoun-Ah Kim, Yong-Beom Park, Seong Wook Kang, Seung-Ki Kwok, Seong-Kyu Kim, Eon Jeong Nam, Yoon-Kyoung Sung, Jaejoon Lee, Chang Hoon Lee, Chan Hong Jeon, Shin-Seok Lee

Erschienen in: Clinical Rheumatology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.
Literatur
2.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed
3.
Zurück zum Zitat Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15–25CrossRefPubMed Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15–25CrossRefPubMed
4.
Zurück zum Zitat Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25CrossRefPubMedPubMedCentral Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 68:1–25CrossRef Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 68:1–25CrossRef
6.
Zurück zum Zitat Bae SC, Kim J, Choe JY et al (2017) A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis 76:65–71CrossRefPubMed Bae SC, Kim J, Choe JY et al (2017) A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis 76:65–71CrossRefPubMed
7.
Zurück zum Zitat Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613–1620CrossRefPubMedPubMedCentral Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613–1620CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Nam JL, Ramiro S, Gaujoux-Viala C et al (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73:516–528CrossRefPubMed Nam JL, Ramiro S, Gaujoux-Viala C et al (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73:516–528CrossRefPubMed
9.
Zurück zum Zitat Du Pan SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560–568CrossRefPubMed Du Pan SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560–568CrossRefPubMed
10.
Zurück zum Zitat Gomez-Reino JJ, Carmona L, Group B (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29CrossRefPubMedPubMedCentral Gomez-Reino JJ, Carmona L, Group B (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Harrold LR, Reed GW, Kremer JM et al (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74:430–436CrossRefPubMed Harrold LR, Reed GW, Kremer JM et al (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74:430–436CrossRefPubMed
12.
Zurück zum Zitat Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47:507–513CrossRef Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47:507–513CrossRef
13.
Zurück zum Zitat Navarro Coy NC, Brown S, Bosworth A et al (2014) The ‘Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord 15:452CrossRefPubMedPubMedCentral Navarro Coy NC, Brown S, Bosworth A et al (2014) The ‘Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord 15:452CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Soderlin MK, Geborek P (2008) Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 67:37–42CrossRefPubMed Soderlin MK, Geborek P (2008) Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis 67:37–42CrossRefPubMed
15.
Zurück zum Zitat Zhang J, Xie F, Delzell E et al (2013) Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) 65:1743–1751CrossRef Zhang J, Xie F, Delzell E et al (2013) Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) 65:1743–1751CrossRef
16.
Zurück zum Zitat Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20CrossRefPubMed Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20CrossRefPubMed
17.
Zurück zum Zitat Kang JH, Park DJ, Lee JW et al (2014) Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci 29:1205–1211CrossRefPubMedPubMedCentral Kang JH, Park DJ, Lee JW et al (2014) Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci 29:1205–1211CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Spalding JR, Hay J (2006) Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. PharmacoEconomics 24:1221–1232CrossRefPubMed Spalding JR, Hay J (2006) Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. PharmacoEconomics 24:1221–1232CrossRefPubMed
19.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
20.
Zurück zum Zitat Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108PubMed Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108PubMed
21.
Zurück zum Zitat Somasinghe TN, Clarke B, Panthakalam S (2014) The Simplified Disease Activity Index (Sdai) and Clinical Disease Activity Index (Cdai) scores as alternatives to the current Das28 score. Ann Rheum Dis 73:902–902CrossRef Somasinghe TN, Clarke B, Panthakalam S (2014) The Simplified Disease Activity Index (Sdai) and Clinical Disease Activity Index (Cdai) scores as alternatives to the current Das28 score. Ann Rheum Dis 73:902–902CrossRef
22.
Zurück zum Zitat Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35:2136–2147CrossRefPubMed Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35:2136–2147CrossRefPubMed
23.
Zurück zum Zitat Neovius M, Arkema EV, Olsson H et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74:354–360CrossRefPubMed Neovius M, Arkema EV, Olsson H et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74:354–360CrossRefPubMed
24.
Zurück zum Zitat Gerhold K, Richter A, Schneider M et al (2015) Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford) 54:1858–1866CrossRef Gerhold K, Richter A, Schneider M et al (2015) Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford) 54:1858–1866CrossRef
25.
Zurück zum Zitat Tubach F, Salmon-Ceron D, Ravaud P, Mariette X, Group RS (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 72:456–460CrossRefPubMed Tubach F, Salmon-Ceron D, Ravaud P, Mariette X, Group RS (2005) The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 72:456–460CrossRefPubMed
26.
Zurück zum Zitat Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32CrossRefPubMed Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32CrossRefPubMed
27.
Zurück zum Zitat Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C et al (2012) Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 71:382–385CrossRefPubMed Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C et al (2012) Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 71:382–385CrossRefPubMed
28.
Zurück zum Zitat Kalkan A, Roback K, Hallert E, Carlsson P (2014) Factors influencing rheumatologists’ prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci 9:153CrossRefPubMedPubMedCentral Kalkan A, Roback K, Hallert E, Carlsson P (2014) Factors influencing rheumatologists’ prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci 9:153CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ogale S, Hitraya E, Henk HJ (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 12:204CrossRefPubMedPubMedCentral Ogale S, Hitraya E, Henk HJ (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 12:204CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53:1664–1668CrossRef Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53:1664–1668CrossRef
31.
Zurück zum Zitat Finckh A, Ciurea A, Brulhart L et al (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387–393CrossRefPubMed Finckh A, Ciurea A, Brulhart L et al (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387–393CrossRefPubMed
32.
Zurück zum Zitat Kaufmann J, Feist E, Roske AE, Schmidt WA (2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 32:1347–1355CrossRefPubMed Kaufmann J, Feist E, Roske AE, Schmidt WA (2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 32:1347–1355CrossRefPubMed
33.
Zurück zum Zitat Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550CrossRefPubMed Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550CrossRefPubMed
34.
Zurück zum Zitat Backhaus M, Kaufmann J, Richter C et al (2015) Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 34:673–681CrossRefPubMedPubMedCentral Backhaus M, Kaufmann J, Richter C et al (2015) Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol 34:673–681CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509CrossRefPubMed Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509CrossRefPubMed
36.
Zurück zum Zitat Strand V, Williams S, Miller PSJ, Saunders K, Grant S, Kremer JM (2013) Discontinuation of biologic therapy in rheumatoid arthritis (Ra): analysis from the Consortium of Rheumatology Researchers of North America (Corrona) database. Ann Rheum Dis 72:71–72 Strand V, Williams S, Miller PSJ, Saunders K, Grant S, Kremer JM (2013) Discontinuation of biologic therapy in rheumatoid arthritis (Ra): analysis from the Consortium of Rheumatology Researchers of North America (Corrona) database. Ann Rheum Dis 72:71–72
37.
Zurück zum Zitat Potter C, Hyrich KL, Tracey A et al (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68:69–74CrossRefPubMed Potter C, Hyrich KL, Tracey A et al (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68:69–74CrossRefPubMed
38.
Zurück zum Zitat van der Heijde D, Klareskog L, Landewe R et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928–3939CrossRefPubMed van der Heijde D, Klareskog L, Landewe R et al (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928–3939CrossRefPubMed
39.
Zurück zum Zitat Burmester GR, Ferraccioli G, Flipo RM et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32–41CrossRefPubMed Burmester GR, Ferraccioli G, Flipo RM et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32–41CrossRefPubMed
40.
Zurück zum Zitat Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68:1346–1352CrossRefPubMed Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68:1346–1352CrossRefPubMed
41.
Zurück zum Zitat Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 43:9–17CrossRefPubMed Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 43:9–17CrossRefPubMed
42.
Zurück zum Zitat Hetland ML, Lindegaard HM, Hansen A et al (2008) Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 67:1023–1026CrossRefPubMed Hetland ML, Lindegaard HM, Hansen A et al (2008) Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 67:1023–1026CrossRefPubMed
43.
Zurück zum Zitat Sato E, Tanaka E, Ochiai M et al (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol 25:350–357CrossRefPubMed Sato E, Tanaka E, Ochiai M et al (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol 25:350–357CrossRefPubMed
44.
Zurück zum Zitat Zhang J, Shan Y, Reed G et al (2011) Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken) 63:1672–1679CrossRef Zhang J, Shan Y, Reed G et al (2011) Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken) 63:1672–1679CrossRef
45.
Zurück zum Zitat Nusslein HG, Alten R, Galeazzi M et al (2014) Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 15:14CrossRefPubMedPubMedCentral Nusslein HG, Alten R, Galeazzi M et al (2014) Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 15:14CrossRefPubMedPubMedCentral
Metadaten
Titel
Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry
verfasst von
Dong-Jin Park
Sung Jae Choi
Kichul Shin
Hyoun-Ah Kim
Yong-Beom Park
Seong Wook Kang
Seung-Ki Kwok
Seong-Kyu Kim
Eon Jeong Nam
Yoon-Kyoung Sung
Jaejoon Lee
Chang Hoon Lee
Chan Hong Jeon
Shin-Seok Lee
Publikationsdatum
27.02.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 5/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3584-y

Weitere Artikel der Ausgabe 5/2017

Clinical Rheumatology 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.